Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold

Key Points

• Wall Street Zen upgraded Century Therapeutics (NASDAQ:IPSC) from a "sell" to a "hold" rating.
• Analyst coverage is mixed — four Buys, two Holds and one Sell — resulting in an average Hold rating and a consensus target price of $4.25.
• Shares trade near $2.31 with a market cap of about $416.6M; the company reported a Q1 EPS loss of ($0.25) that beat estimates and is a clinical‑stage biotech developing iPSC-derived "off-the-shelf" NK and T cell therapies.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Sunday.

A number of other analysts also recently commented on IPSC. Leerink Partners set a $2.00 price objective on Century Therapeutics and gave the stock a "market perform" rating in a research report on Friday, March 13th. Piper Sandler raised their price objective on Century Therapeutics from $2.00 to $4.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 20th. TD Cowen initiated coverage on Century Therapeutics in a research report on Wednesday, February 25th. They issued a "buy" rating for the company. Zacks Research downgraded Century Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, March 12th. Finally, HC Wainwright raised their price objective on Century Therapeutics from $2.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday, April 21st. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $4.25.

Century Therapeutics Stock Up 0.9%

Shares of NASDAQ IPSC opened at $2.31 on Friday. The business has a fifty day simple moving average of $2.32 and a 200-day simple moving average of $1.53. Century Therapeutics has a 12 month low of $0.44 and a 12 month high of $3.04. The company has a market cap of $416.61 million, a price-to-earnings ratio of -16.50 and a beta of 1.55.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.04. As a group, sell-side analysts expect that Century Therapeutics will post -0.63 EPS for the current fiscal year.

Insider Transactions at Century Therapeutics

In other Century Therapeutics news, insider Gregory Russotti sold 10,076 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total transaction of $25,693.80. Following the completion of the transaction, the insider directly owned 515,427 shares in the company, valued at $1,314,338.85. This represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 17,921 shares of company stock worth $45,458 in the last three months. Corporate insiders own 4.37% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IPSC. Prudential Financial Inc. acquired a new position in Century Therapeutics during the second quarter worth $25,000. Qube Research & Technologies Ltd acquired a new position in Century Therapeutics during the second quarter worth $38,000. Raymond James Financial Inc. acquired a new position in Century Therapeutics during the second quarter worth $51,000. AQR Capital Management LLC raised its stake in Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after acquiring an additional 86,875 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after acquiring an additional 34,466 shares in the last quarter. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.